Skip to content
COVID19, Medical Health Aged Care

RESEARCH REVEALS HOW COVID-19 VIRUS INFECTS THE PLACENTA, AND HOW THIS CAN BE PREVENTED

Monash University 2 mins read

RESEARCH REVEALS HOW COVID-19 VIRUS INFECTS THE PLACENTA, AND HOW THIS CAN BE PREVENTED

In a landmark study published today (TBC) in Nature Cell Biology, Australian researchers, led by Professor Jose Polo from Monash University and the University of Adelaide and University of Melbourne’s Professor Kanta Subbarao from the Peter Doherty Institute for Infection and Immunity (Doherty Institute), have revealed how COVID-19 can infect the human placenta.

Research has shown that COVID-19 infections during pregnancy may lead to adverse outcomes, but little is known about the mechanisms behind the effects of SARS-CoV-2 infection in pregnancy.

The Australian research team grew placenta tissue in the lab, using a state-of-the-art method developed by Professor Polo and colleagues where human skin cells are "reprogrammed" into trophoblast stem cells (the cells that help a developing embryo attach to the wall of the uterus, forming part of the placenta). They found that ACE2, a protein that acts as the doorway for SARS-CoV-2 to enter organs such as the lung, is present in specific placental cells, like syncytiotrophoblasts (ST cells).

Importantly, ST cells were susceptible to the virus – a major finding as these placental cells produce the key hormone for maintaining pregnancy (hCG).

Dr Joseph Chen, a stem cell biologist at Monash University and co-first author of the report, said this discovery explains several clinical reports indicating inflammation of the placenta due to COVID-19.

“We observed that SARS-CoV-2 infection led to a significant reduction in the survival and differentiation of ST cells, which in turn resulted in lower production of hCG,” he said.

“It suggests that this is how COVID-19 could impact pregnancy, though further investigations are needed.”

Virologist at Doherty Institute and co-first author of the study Dr Jessica Neil said, “our team also discovered that anti-ACE2 antibodies and antiviral drugs were effective in preventing SARS-CoV-2 infection and restoring normal ST differentiation and function”.

Professor Subbarao said that this study is a significant advance for the broader understanding of viral infections in pregnancy.

“Our study provides valuable insights into the link between SARS-CoV-2 infection and placenta pathology. This is a game changer as we are now equipped to explore how the early placenta may be affected by other viruses as well,” she said.

Professor Polo emphasised the importance of the research in establishing a platform to study early placental cell types.

“This study not only helps us to understand what happens when the placenta is infected with the COVID-19 virus during pregnancy, it also means we have established a broader, scalable and tractable platform to study early placental cell types,” he said.

 

------

 

 


Contact details:

Tania Ewing 0408378422

taniaewing@taniaewing.com

Media

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.